Non-animal chondroitin sulfate for joint support
Chondroitin sulfate (CS) is a naturally occurring glycosaminoglycan mainly present in cartilage. In this tissue, it plays a key role in maintaining structure, elasticity, and hydration.
In joint cartilage, it is a key component of proteoglycans, molecules that help the tissue absorb shocks and resist pressure. This essential role makes it a widely used ingredient in joint health supplements.
Traditionally, CS used in dietary supplements and pharmaceuticals has been extracted from animal sources such as bovine, porcine, avian, and marine tissues. However, animal-derived CS often shows variability in quality, structure, and purity, and its bioavailability remains limited.
MyCondro™ is the first non-animal chondroitin sulfate (CS) produced through a patented fermentation process.
It addresses the limitations of traditional animal-derived CS by offering a highly purified, homogeneous structure, low molecular weight, and consistent batch quality.
It also provides an excellent safety profile, eliminating risks of contamination from animal materials.
Another key advantage of MyCondro™ is its superior bioavailability, allowing effective results at a significantly lower daily dosage — just 600 mg compared to the typical 1,200 mg required with animal-derived CS.
Its efficacy, safety, and tolerability have been demonstrated in randomized, double-blind, placebo-controlled clinical trials involving subjects with moderate knee osteoarthritis.
With its clean-label, vegan, and sustainable profile, MyCondro™ offers supplement manufacturers a clinically proven, evidence-based alternative to animal-derived CS, meeting the growing demand for effective, safer solutions to support joint health.
Evidence-based mechanism of action of chondroitin sulfate in joint health
Chondroitin sulfate (CS) is naturally produced by the body and present in connective tissues, particularly in cartilage. It retains water in the extracellular matrix, ensuring hydration, elasticity, and mechanical strength. This water-binding capacity is especially important in joint cartilage, where CS cushions the bones and absorbs shocks during movement.
CS helps protect chondrocytes, the cells responsible for producing cartilage components, by reducing the impact of inflammatory or hypoxic stress. This protective effect helps maintain cartilage integrity and contributes to long-term joint health.
It also protects cartilage by inhibiting enzymes that break it down, while stimulating the production of key structural components such as collagen and aggrecan.
In addition, CS reduces the production of inflammatory mediators in synoviocytes (joint-lining cells), helping to control inflammation within the joint environment.
Through these combined actions, CS plays a crucial role in preserving the resilience, structure, and function of joint tissues over time.
Structural advantages of fermentation-derived chondroitin sulfate
The fermentation process produces a non-animal chondroitin sulfate (CS) with a homogeneous profile, low polydispersity, and consistent physicochemical properties from batch to batch. This high level of control results in exceptional purity, with more than 95% chondroitin sodium sulfate, exceeding the USP standard of 90%.
Its low molecular weight design, around 9 kDa, enhances intestinal absorption and tissue distribution.
Unlike animal-derived sources, fermentation-derived CS is free from viruses, prions, allergens, and residual animal proteins.
The innovative production method and composition are protected by five international patents, ensuring both quality and exclusivity.
Superior bioavailability of fermentation-derived chondroitin sulfate compared to animal-derived
The low molecular weight of fermentation-derived chondroitin sulfate (CS) significantly enhances its bioavailability. In a pharmacokinetic study published in Clinical Pharmacology in Drug Development (2018), researchers compared the absorption profile of non-animal chondroitin sulfate (MyCondro™, Gnosis S.p.A., Italy) with that of pharma grade bovine-derived CS in healthy male volunteers over a 48-hour period.
Following a single 2,400 mg oral dose of each formulation, total CS levels were measured in plasma. The non-animal CS demonstrated an overall greater plasma concentration, approximately +44% after 24 hours and +45% after 48 hours, compared to the animal-derived counterpart. Notably, the bovine CS used in this study was pharmaceutical grade, meaning the observed superior bioavailability of the fermentation-derived CS is even more significant when compared to standard nutraceutical-grade materials.
Furthermore, the fermentation-derived CS maintained higher concentrations in plasma for a longer duration, supporting more efficient delivery to joint tissues.
Importantly, the safety and tolerability profile after a single dose was excellent.
Clinical evidence supporting the efficacy of fermentation-derived chondroitin sulfate in moderate osteoarthritis
Fermentation-derived chondroitin sulfate (MyCondro™) has shown significant benefits for individuals with moderate knee osteoarthritis, even at a low dosage of 600 mg/day, half the amount typically used for animal-derived CS (800–1,200 mg/day).
Its efficacy and safety have been confirmed in two randomized, double-blind, placebo-controlled clinical trials, with no major side effects reported and good tolerability for long-term use.
Study 1 : 3-Month Clinical Trial in Moderate Knee Osteoarthritis, Rondanelli M. et al., Nutrients 2019
In this randomized, double-blind, placebo-controlled pilot study, 60 overweight adults with symptomatic moderate knee osteoarthritis took either 600 mg/day of fermentation-derived chondroitin sulfate (MyCondro™) or a placebo for 12 weeks.
Researchers monitored knee pain, quality of life, inflammation markers (CRP and ESR levels), and body composition at the start, 4 weeks, and 12 weeks.
Knee health was evaluated using the WOMAC (Western Ontario and McMaster Universities) Index and the Tegner Lysholm Knee Score (TLKS).
Key findings:
- Improved knee function: Participants taking MyCondro™ reported a TLKS noticeably better demonstrating improved joint mobility and daily function compared to the placebo group.
- Reduced knee pain: WOMAC assessments showed significant pain relief during everyday activities such as walking, climbing stairs, and standing. These findings were further confirmed using the Visual Analog Scale (VAS), providing additional evidence of the robust analgesic effect of MyCondro™ supplementation.
- Lower inflammation: Blood tests indicated a clear reduction in CRP and ESR, markers of joint inflammation.
These results confirmed that three months of supplementation with MyCondro™ provided measurable benefits for knee comfort, mobility, and inflammation in individuals with moderate osteoarthritis.
Study 2 : Short- and Long-Term Benefits in Obese Adults with Moderate Knee Osteoarthritis, Rondanelli M. et al., Antioxidants 2020
In this randomized, double-blind, placebo-controlled trial, 48 obese adults with moderate knee osteoarthritis received either 600 mg/day of fermentation-derived chondroitin sulfate (MyCondro™) or a placebo for 8 weeks.
Researchers evaluated inflammation, functional status, oxidative stress, cartilage breakdown markers, metabolic profile, and body composition. Assessments were performed at baseline, after 15 days, and at the end of the study.
Key findings:
- Improved function and reduced pain: WOMAC scores showed greater improvement in the MyCondro™ group compared to placebo.
- Reduced inflammation at rest and after physical stress: To test acute effects, participants performed a 15-minute cycling session 15 days after starting supplementation and again at week 8. In the MyCondro™ group, C-reactive protein (CRP) levels were lower both at rest and after exercise, indicating better control of inflammation in everyday and physically demanding situations.
- Metabolic benefits: Participants taking MyCondro™ experienced reductions in BMI, total cholesterol, and insulin resistance (HOMA-IR), likely linked to increased activity resulting from pain relief, reflecting the analgesic effect of MyCondro™.
These results confirm and expand on earlier studies, showing that MyCondro™ not only supports joint function and reduces pain, but also helps manage inflammation under both resting and active conditions.
MyCondro™ Fermentation-Based Chondroitin Sulfate: Clinically Supported Solution for Osteoarthritis Support (= conclusion)
MyCondro™ combines scientific credibility, technical consistency, and ethical advantages, making it a next-generation ingredient for premium joint health dietary supplements.
Its evidence-based benefits include:
- Higher bioavailability than animal-derived chondroitin sulfate (+45%).
- Clinically demonstrated efficacy in randomized, placebo-controlled trial at a low daily dose (600 mg).
- Excellent tolerability, suitable for long-term use.
- Clean-label credentials: vegan, allergen-free, non-GMO.
- Sustainability: produced from abundant and reproducible microorganisms, avoiding pressure on marine ecosystems and animal resources.
Clinically observed benefits in individuals with moderate knee osteoarthritis:
- Reduced knee pain and improved comfort.
- Enhanced knee function and mobility.
- Lower joint inflammation, as shown by decreased CRP and ESR levels.
- Improved overall perception of joint health.
- Support for staying active and maintaining daily activities.[Text Wrapping Break]
Formulation flexibility: MyCondro™ can be used alone or in combination with other joint health ingredients (such as glucosamine, MSM, or collagen) to create innovative dietary supplement formulations.
References :
